According to Yifan Pharmaceutical's announcement, the company's holding subsidiaries, Yiyi Biomedical Development Co., Ltd. and Yiyi Biopharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and agreed that Yiyi Biotech will conduct phase II clinical trials on the treatment of graft versus host disease using recombinant human interleukin 22-FC fusion protein in the product being developed for injectable injection. The drug is registered and classified as a therapeutic biological product class 1. As of the disclosure date of this report, no identical target products have been approved for marketing at home and abroad, and no identical target products are undergoing clinical development for GVHD indications.

According to Yifan Pharmaceutical's announcement, the company's holding subsidiaries, Yiyi Biomedical Development Co., Ltd. and Yiyi Biopharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and agreed that Yiyi Biotech will conduct phase II clinical trials on the treatment of graft versus host disease using recombinant human interleukin 22-FC fusion protein in the product being developed for injectable injection. The drug is registered and classified as a therapeutic biological product class 1. As of the disclosure date of this report, no identical target products have been approved for marketing at home and abroad, and no identical target products are undergoing clinical development for GVHD indications.